Formula rebounds, Amerifit grows in Martek Q2
This article was originally published in The Tan Sheet
Executive Summary
The infant formula market's rebound from 2009 lows helps boost Martek Biosciences' total product sales 35.1 percent to $119.1 million in the February-April period. Second-quarter sales of Martek's formula ingredients reached $86.3 million, up 11.5 percent, helped by gains in Asia, executives said June 3. Amerifit Brands, which Columbia, Md.-based Martek acquired in January, generated $18 million in revenue and $1.9 million in operating income. Martek plans to launch finished supplement products through Amerifit in 2011 (1"The Tan Sheet" Jan. 25, 2010). Additionally, the company continues seeking new applications for its algal life'sDHA. Martek announced June 2 the omega-3 ingredient will fortify sauces and dressings at sandwich chain Quiznos
You may also be interested in...
Martek Pursues Direct Consumer Access With Pending Acquisition Of Amerifit
Martek Biosciences' proposed acquisition of Amerifit Brands for $200 million would mark the omega-3 DHA ingredient supplier's first major foray into consumer marketing and would substantially expand the firm's portfolio
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.